The latest announcement is out from Targovax ASA ( (GB:0RIS) ).
Circio Holding ASA has secured additional funding from Atlas through the issuance of convertible bonds worth NOK 4,000,000, ensuring operational financing until June 2025. This financial move supports Circio’s continued development of its innovative RNA technologies and cancer vaccine initiatives, potentially strengthening its position in the biotechnology sector.
More about Targovax ASA
Circio Holding ASA is a biotechnology firm focused on developing advanced RNA technology for nucleic acid medicine. The company has created a unique circular RNA vector expression platform, circVec, which enhances protein expression significantly compared to traditional mRNA systems. Circio is also working on a cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway.
YTD Price Performance: -94.01%
Average Trading Volume: 21,533
Technical Sentiment Signal: Buy
Current Market Cap: NOK56.17M
See more insights into 0RIS stock on TipRanks’ Stock Analysis page.